The uptake of proton beam therapy has been slower in the UK compared with other developed countries; however, this is…
Browsing: Acute Lymphoblastic Leukemia
Since 2004, over 20 new proton beam centers, a type of radiation primarily identified as being effective in treating pediatric…
Radiation therapy is well established as one of the three primary approaches to treating cancer; however, it comes with a…
CAR-T cell therapy is an innovative new strategy that may revolutionize lymphoma treatment. Speaking from the 2017 National Cancer Research…
New studies are constantly evolving the field of lymphoma research, with trials continuously striving to find more effective treatments. At…
As the roles of various proteins within the human body become clearer, novel research can develop to produce effective therapies…
To efficiently produce effective therapies, it is necessary for experts within different specialties to collaborate. At the International Conference on…
Immunotherapy has emerged in recent years as a promising lymphoma treatment, with exciting new drug classes being developed with innovative…
As the finer details of how therapies interact within the body become clear, novel research to create more effective medications…
To produce safe and effective therapies for patients, novel research must first occur in cell culture systems. In this interview,…
There are two well-known checkpoint inhibitors that have shown efficacy in relapses/refractory Hodgkin lymphoma, nivolumab and pembrolizumab, both PD-1 inhibitors.…
Francine Foss, MD, from the Yale University School of Medicine, New Haven, CT, discusses targeting chemokines at the International Workshop…
“Both targeted agents, such as brentuximab vedotin, and checkpoint inhibitors, such as pembrolizumab, have shown activity in a subset of…
Dr. Jack West addresses the question of whether the data with various PD-1 and PD-L1 inhibitors in lung cancer management…
Patients who are actively engaged with their diagnosis, treatment and symptoms now have an outlet to share their treatment journey…
Neeraj Agarwal, MD Associate Professor of Medicine Director, Genitourinary Oncology Co-leader, Urologic Oncology Multidisciplinary Program Huntsman Cancer Institute, University of…
Pavlos Msaouel MD, PhD Chief Fellow, Hematology/Oncology MD Anderson Cancer Center discusses Renal Medullary Carcinoma at the 2017 Kidney Cancer…
MOASC Educational Series 2017 roundtable discussion on oncology billing and the new challenges.
Remy Turner presents the options available to providers to follow-up on claims that have been submitted for payment. Timeliness and…
Dawn Holcombe, MBA, FACMPE, ACHE DGH Consulting discusses Pharmacy Standards in transition and real at the MOASC Educational Series 2017
Elaine L. Towle, CMPE discusses MACRA and MIPS and an Oncology Billing Update: And Whats new for 2018? from the…
Dr. Jack West reviews the implications of the PACIFIC trial that establishes a role for durvalumab immunotherapy in stage III…
Christopher Wood, MD, Elizabeth Plimack, MD, Martin Voss, MD, Viraj Masters, MD, A. Ari Hakimi, MD consult on a several…
Brian Shuch, MD Assistant Professor of Urology and Radiology Yale School of Medicine Genomic Heterogeneity and the Small Renal Mass…
Martin Voss, MD Memorial Sloan Kettering discusses Integrated Biomarker Analysis for 412 RCC patients Treated on the Phase 3 COMPARZ…
Sumanta Kumar Pal, M.D City of Hope Cancer Center discusses IMmotion150: Novel Radiological Endpoints and Updated Data From a Randomized…
Comparative Genomic Profiling of Matched Maria Becerra, MD discusses Primary and Metastatic Tumors in Renal Cell Carcinoma at the 2017 Kidney Cancer Association…
Vadim S. Koshkin, MD Cleveland Clinic Taussig Cancer discusses Clinical Activity of Nivolumab in Patients with Non-Clear Cell Renal Cell…
Christopher G. Wood, M. D., FACS Professor and Deputy Chairman Douglas E. Johnson, M. D. Endowed Professorship In Urology Department…
Ronald M. Bukowski, MD discusses Training Medical Oncologists to be Experts in RCC at the 2017 Kidney Cancer Association symposium…
Martin Voss, MD Genitourinary Oncology Service Memorial Sloan Kettering Cancer Center, New York gives an Update on Genomic Classifiers in…
Joshua M. Lang, MD University of Wisconsin School of Medicine and Public Health discusses Circulating Biomarkers in Clear Cell Renal…
Payal Kapur, M.D. Associate Professor of Pathology and Urology, UTSW Group Leader Genitourinary Pathology, UTSW Kidney Cancer Program co-leader, Simmons…
Leigh Ellis Ph.D. Assistant Professor Department of Oncologic Pathology Dana-Farber Cancer Institute Brigham and Womens Hospital Harvard Medical School discusses…
Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery Affiliate Member Department of Computational Biology discusses Cell line and…
Viraj A. Master of Emory University discusses Neoadjuvant Presurgical Therapy for RCC: Lessons Learned at the 2017 Kidney Cancer Association…
Tim Eisen University of Cambridge discusses Perspective(s) on Adjuvant Trials at the 2017 Kidney Cancer Association symposium in Miami, FL.
Grant D Stewart BSc, MBChB, FRCSEd (Urol), PhD University Lecturer and Consultant in Urological Surgery, Academic Urology Group, University of…
Axel Bex, MD, PhD The Netherlands Cancer Institute Amsterdam, The Netherlands outlines the Challenges in SURTIME and CARMENA at the…
Mark W. Ball, MD Staff Clinician | Assistant Research Physician Urologic Oncology Branch National Cancer Institute National Institutes of Health…
Steven C. Campbell, MD, PhD Program Director, Vice Chairman Department of Urology Center for Urologic Oncology Glickman Urological and Kidney…
Rodolfo Borges dos Reis MD; PhD. Head of Uro-oncology Ribeirão Preto Medical School The University of São Paulo answers teh…
R. Houston Thompson, MD Professor of Urology Mayo Clinic, Rochester, MN @HThompsonMD presents Guidelines on Managing SRMs: Compare and Contrast…
John T. Leppert, MD MS Associate Professor, Stanford University Director of Urologic Oncology, VA Palo Alto @johnleppert presents Nephrometry: 21st…
Loren Tarantino, MS SMP Global Partner discusses Systems Thinking Approach to Strategic Management at the MOASC educational series on November…
Roberta Buell Principal, On Point Oncology presents the Revenue Cycle State of the State: Where are we? How can we…
Elaine L. Towle, CMPE Division Director, Analysis & Consulting Services Clinical Affairs provides an in-depth look at the MACRA Quality…
Merrianne Do, Pharm D of Walgreen’s discusses it’s new pilot program for specialty oncology drugs at the MOASC educational series…
Andrew W. Hahn, MD University of Utah Huntsman Cancer Institute @onchahn discusses Predictive genomic markers of response to VEGF targeted…
IRINA PROSKOROVSKY, MSC discusses Axitinib and Cabozantinib in the Treatment of Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma (mRCC): Results…